Research programme: receptor tyrosine kinase inhibitors - ChemDiv/Oncalis

Drug Profile

Research programme: receptor tyrosine kinase inhibitors - ChemDiv/Oncalis

Alternative Names: ONC-101

Latest Information Update: 29 Oct 2008

Price : $50

At a glance

  • Originator ChemDiv; Oncalis
  • Class Small molecules
  • Mechanism of Action EphB4 inhibitors; Epidermal growth factor inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Oct 2008 Preclinical development is ongoing in USA and Switzerland
  • 05 Oct 2006 Preclinical trials in Cancer in Russia (unspecified route)
  • 05 Oct 2006 Oncalis and ChemDiv have entered into an agreement to discover and develop receptor tyrosine kinase inhibitors for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top